Novartis Alters Zometa Study Design Due To Renal Function Concerns
Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.
Novartis is eliminating the 8 mg Zometa arm of its ongoing bone metastases studies, following the detection of elevated serum creatinine levels in some patients.